NAV

BCG vaccine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
BCG vaccine
Accession Number
DB12768
Description

BCG vaccine has been investigated for the treatment of Neoplasms, Bladder Cancer, Neoplasms by Site, Urologic Diseases, and Urologic Neoplasms, among others.

Type
Biotech
Groups
Investigational
Biologic Classification
Vaccines
Other vaccines
Synonyms
  • Bacillus calmette-guerin live antigen, unspecified substrain
  • BCG

Pharmacology

Indication
Not Available
Associated Conditions
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Unlock Additional Data
AbacavirThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Abacavir.
AbataceptThe risk or severity of infection can be increased when BCG vaccine is combined with Abatacept.
Acetic acidThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Acetic acid.
Acetyl sulfisoxazoleThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Acetyl sulfisoxazole.
AcyclovirThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Acyclovir.
AdalimumabThe risk or severity of infection can be increased when BCG vaccine is combined with Adalimumab.
Adefovir dipivoxilThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Adefovir dipivoxil.
AldesleukinThe risk or severity of infection can be increased when BCG vaccine is combined with Aldesleukin.
AlefaceptThe risk or severity of infection can be increased when BCG vaccine is combined with Alefacept.
AlemtuzumabThe risk or severity of infection can be increased when BCG vaccine is combined with Alemtuzumab.
Additional Data Available
  • Extended Description
    Extended Description
    Available for Purchase

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity
    Available for Purchase

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level
    Available for Purchase

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action
    Available for Purchase

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Categories

ATC Codes
L03AX03 — Bcg vaccine
Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
8VJE55B0VG
CAS number
Not Available

References

General References
  1. TITCK Product Information: Calgevax-BCG (BCG for immunotherapy) powder for intravesical injection [Link]
  2. TITCK Product Information: SII-BCG (BCG vaccine, live, attenuated) powder for suspension for intradermal injection [Link]
PubChem Substance
347911376
RxNav
1344
Wikipedia
BCG_vaccine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Active Not RecruitingPreventionCoronavirus Disease 2019 (COVID‑19)1
4CompletedPreventionBCG Infection / Immune Response / Reaction - Vaccine1
4CompletedPreventionClinical / Intervention / Prospective / Single-blind / Trial1
4CompletedPreventionTuberculosis (TB)1
4RecruitingPreventionAbsenteeism / Coronavirus Disease 2019 (COVID‑19) / Morbidity1
4RecruitingPreventionChronic Obstructive Pulmonary Disease (COPD) / Coronary Heart Disease (CHD) / Coronavirus Disease 2019 (COVID‑19) / Infections, Coronavirus / Virus Diseases1
4RecruitingPreventionCoronavirus as the Cause of Diseases Classified Elsewhere / Coronavirus Disease 2019 (COVID‑19) / Infections, Coronavirus1
4RecruitingPreventionCoronavirus Disease 2019 (COVID‑19) / Respiratory Tract Infections (RTI)1
4RecruitingTreatmentBCG / Coronavirus Disease 2019 (COVID‑19) / SARS-CoV 2 / Therapeutic Vaccine / Transmission1
4TerminatedPreventionPlasmodium Infections1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SolutionIntravesical30 mg
Powder, for solutionIntravesical1600000000 U
Powder, for suspensionIntravesical1600000000 units
Injection, powder, for solutionIntravesical81 mg
Powder, for suspensionIntravesical1600000000 U
Injection, powder, lyophilized, for solutionIntravesical11.25 mg
Injection, powder, for suspensionIntradermal0.5 mg
Injection, powder, for suspensionIntravesical81 mg
Injection, powder, lyophilized, for solutionIntravesical81 mg
Powder, for suspensionIntravesical500000000 CFU
Injection, powder, lyophilized, for solutionIntradermal500,000 CFU/0.1ml
InjectionIntradermal0.1 ml
Injection, powder, lyophilized, for suspensionIntravesical40 mg/ml
Injection, powder, for solutionIntravesical0.375 MG/ML
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on October 20, 2016 18:07 / Updated on October 24, 2020 01:30

69